Acadia Pharmaceuticals (ACAD) FY2014 results: revenue $120,000, down 89.5% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $120,000 for fiscal 2014, the year ended 31 December 2014, down 89.5% on the year before. Net income was -$92 million, and diluted earnings per share $-0.95. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2015.
Revenue
$120,000
-89.5% on the year
FY2009FY2014
Operating margin
-77691.7%
-3344.7% a year earlier
FY2009FY2014
Net income
-$92 million
FY2009FY2014
Diluted EPS
-$0.95
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
0.1
1.1
4.9
-89.5%
Research and development
60.6
26.7
18.8
+126.8%
Selling, general and administrative
32.7
n/a
n/a
Operating income
-93.2
-38.3
-20.9
Operating margin
-77691.7%
-3344.7%
-425.6%
Pre-tax income
-92.5
-37.9
n/a
Income tax
0.0
0.0
0.0
Net income
-92.5
-37.9
-20.8
Net margin
-77062.5%
-3314.2%
-424.9%
Diluted EPS
-$0.95
-$0.44
-$0.38
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
-66.4
-31.8
-21.6
Capital expenditure
0.2
0.6
n/a
-70.9%
Free cash flow
-66.6
-32.4
n/a
Free cash flow margin
-55511.7%
-2828.6%
n/a
Cash from investing
n/a
n/a
-25.5
Cash from financing
n/a
n/a
98.2
Depreciation and amortisation
0.2
0.1
0.1
+160.8%
Share-based compensation
16.0
5.7
1.9
+180.8%
Diluted shares, weighted
n/a
n/a
55m
Shares outstanding at period end
100m
91m
73m
+9.8%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
309
182
85.0
+69.9%
Other liabilities
16.0
7.0
23.6
+128.6%
Total liabilities and equity
325
189
109
+72.1%
Fixed assets
0.6
0.6
0.0
-4.5%
Investments
261
174
50.1
+49.7%
Cash and equivalents
61.9
11.7
57.9
+428.4%
Other assets
2.4
2.7
0.6
-12.0%
Total assets
325
189
109
+72.1%
10-K for the year ended 31 December 2014, filed 26 February 2015: the filing.